Brainsway looks to Nasdaq offering

D Medical's experience last week demonstrated that obtaining a premium on the TASE market cap is not easy.

Brainsway Ltd. (TASE:BRIN) today announced that it plans to hold an offering on Nasdaq this year. It is undeterred by the difficulties faced by D Medical Industries Ltd. (TASE:DMDC; Nasdaq: DMED) in its Nasdaq offering last week.

Brainsway has developed Deep TMS (Transcranial Magnetic Stimluation) for non-invasive treatment of a range of neurological and psychiatric disorders. The company is joining drug developers BiolineRX Ltd. (TASE:BLRX) and Biocancell Therapeutics Ltd. (TASE:BICL) in plans to hold offerings on Nasdaq. "Globes" was the first to report that Biocancell is seeking to raise $10 million on Wall Street.

Brainsway, run by CEO Uzi Sofer, currently trades at a market cap of NIS 341 million. It had NIS 23 million in cash at the end of March. The company did not disclose how much it wants to raise on Nasdaq, or at what company value. It is also not known whether it will aim for a premium on its market cap on the TASE, but D Medical's experience last week demonstrated that obtaining such a premium is not easy.

Brainsway's share price rose 5.6% by mid-afternoon on the TASE to NIS 8.52.

Published by Globes [online], Israel business news - www.globes-online.com - on August 8, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Yaron Daniely Replacing Ritalin

Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.

Twitter Facebook Linkedin RSS Newsletters